Although a high percentage of breast cancers harbour mutations in genes that constitute the PI3K pathway and the role of the PI3K inhibitor PTEN is well documented, the incidence of PTEN gene mutations in invasive breast cancer is relatively low (less than 7 %) [66,67]. The gene discussed is PTEN; the disease is breast carcinoma.